1. Market Research
  2. > Pharmaceutical Market Trends
  3. > Pakistan Pharmaceuticals and Healthcare Report Q1 2017

Pakistan Pharmaceuticals and Healthcare Report Q1 2017

  • November 2016
  • -
  • Business Monitor International
  • -
  • 108 pages

Includes 3 FREE quarterly updates


BMI View:

The development of Pakistan’s pharmaceutical sector will remain stymied as uncertainty over the country’s pricing regime causes firms to withhold further investments. We do not expect this to improve over the coming quarters as the Drug Regulatory Authority of Pakistan is restrained by both political pressure and its capacity to implement reforms to the pricing regime. This will perpetuate the limited activity of multinational drugmakers, exacerbating the shortage of medicines in the country and potentially driving up demand for counterfeit drugs.

Headline Expenditure Projections



- Pharmaceuticals: PKR252bn (USD2.5bn) in 2015 to PRK274bn (USD2.6bn) 2016; +8.5% in local currency terms and +6.1% in US dollar terms. Forecast unchanged from last quarter.

- Healthcare: PKR740bn (USD7.2bn) in 2015 to PKR810bn (USD7.7bn) in 2016; +9.4% in local currency terms and +7.1% in US dollar terms. Forecast unchanged from last quarter. Risk/Reward Index Pakistan’s Pharmaceutical Risk/Reward Index (RRI) score for Q117 is 41.7 out of 100. This places it 16th out of 19 other markets in the Asia Pacific region. This low score is driven by the below average industry rewards score with a low spending per capita in USD (scoring 1.2 out of 12) as well modest sector value growth (6.0 out of 12.0). Similarly, the country’s instability further drags down the country risk score (12.9 out of 35).

Table Of Contents

Pakistan Pharmaceuticals and Healthcare Report Q1 2017
BMI Industry View 7
Table: Headline Pharmaceuticals and Healthcare Forecasts (Pakistan 2014-2020) 7
SWOT 9
Industry Forecast 11
Pharmaceutical Market Forecast 11
Table: Pharmaceutical Sales, Historical Data And Forecasts (Pakistan 2012-2020) 13
Healthcare Market Forecast 14
Table: Healthcare Expenditure Trends, Historical Data And Forecasts (Pakistan 2012-2020) 17
Table: Government Healt Expenditure Trends, Historical Data And Forecasts (Pakistan 2010-2018) 17
Table: Private Healthcare Expenditure Trends, Historical Data And Forecasts (Pakistan 2012-2020) 18
Prescription Drug Market Forecast 19
Table: Prescription Drug Market Indicators, Historical Data And Forecasts (Pakistan 2012-2020) 21
Patented Drug Market Forecast 22
Table: Patented Drug Market Indicators, Historical Data And Forecasts (Pakistan 2012-2020) 23
Generic Drug Market Forecast 24
Table: Generic Drug Market Indicators, Historical Data And Forecasts (Pakistan 2012-2020) 26
OTC Medicine Market Forecast 27
Table: Over-The-Counter (OTC) Medicine Market Indicators, Historical Data And Forecasts (Pakistan 2012-2020) 29
Pharmaceutical Trade Forecast 30
Table: Pharmaceutical Trade Data And Forecasts (Pakistan 2014-2020) 32
Table: Pharmaceutical Trade Data And Forecasts local currency (Pakistan 2014-2020) 32
Industry Risk/Reward Index 33
Asia Pacific Risk/Reward Index 33
Pakistan Risk/Reward Index 39
Rewards 39
Risks 39
Regulatory Review 41
Intellectual Property Issues 44
Pricing Regime 44
Reimbursement Regime 46
Market Overview 48
Healthcare Sector 49
Table: Healthcare Resources (Pakistan 2010-2015) 51
Table: Healthcare Personnel (Pakistan 2010-2015) 51
Table: Healthcare Activity (Pakistan 2010-2015) 52
Research and Development 52
Clinical Trials 53
Epidemiology 54
Table: Diabetic Patients' Education Level and Compliance Levels 56
Table: Estimated Number Of New Cases Of Cancer In Pakistan 57
Table: Frequency Of Information Provided To Patients As A Percentage Of Total Cases 57
Competitive Landscape 59
Research-Based Industry 59
Table: Multinational Market Activity 59
Generic Drugmakers 60
Table: PPMA As Of 2015 61
Pharmaceutical Distribution 64
Company Profile 66
Abbott Laboratories 66
Efroze Chemical Industries 70
Ferozsons Laboratories 73
Getz Pharma 77
GlaxoSmithKline 80
Hilton Pharma 84
Novartis 86
Pfizer 89
Sanofi-Aventis 92
Searle Pakistan Limited 95
Demographic Forecast 97
Table: Population Headline Indicators (Pakistan 1990-2025) 98
Table: Key Population Ratios (Pakistan 1990-2025) 98
Table: Urban/Rural Population and Life Expectancy (Pakistan 1990-2025) 99
Table: Population By Age Group (Pakistan 1990-2025) 99
Table: Population By Age Group % (Pakistan 1990-2025) 100
Glossary 102
Methodology 104
Pharmaceutical Expenditure Forecast Model 104
Healthcare Expenditure Forecast Model 104
Notes On Methodology 105
Risk/Reward Index Methodology 106
Index Overview 107
Table: Pharmaceutical Risk/Reward Index Indicators 107
Indicator Weightings 108

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
PharmaPoint: Atrial Fibrillation - Global Drug Forecast and Market Analysis to 2025

PharmaPoint: Atrial Fibrillation - Global Drug Forecast and Market Analysis to 2025

  • $ 10995
  • Industry report
  • August 2016
  • by Global Data

PharmaPoint: Atrial Fibrillation - Global Drug Forecast and Market Analysis to 2025 Summary Atrial fibrillation (AF) is the most common cardiac arrhythmia and is a heart condition that causes an irregula ...

PharmaPoint: Venous Thromboembolism - Global Drug Forecast and Market Analysis to 2025

PharmaPoint: Venous Thromboembolism - Global Drug Forecast and Market Analysis to 2025

  • $ 10995
  • Industry report
  • August 2016
  • by Global Data

PharmaPoint: Venous Thromboembolism - Global Drug Forecast and Market Analysis to 2025 Summary Venous thromboembolism (VTE) is a disease that includes a myriad of life-threatening disorders ranging from ...

Global Pharmaceutical Contract Manufacturing Organization (CMO) Market

Global Pharmaceutical Contract Manufacturing Organization (CMO) Market

  • $ 7000
  • Industry report
  • August 2016
  • by Frost & Sullivan

Emerging Business Models Drive Transformation The key objective of this research is to provide in-depth knowledge of the major global pharmaceutical CMO market segments—active pharmaceutical ingredients ...


ref:plp2016

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.